
Opinion|Podcasts|November 22, 2024
Future Landscape of BTK Inhibitors for CSU
Key Takeaways
- Biologics, especially monoclonal antibodies, provide targeted, personalized treatment options in CSU management, improving efficacy and safety profiles.
- BTK inhibitors offer a novel therapeutic approach by modulating B-cell receptor signaling, potentially benefiting patients unresponsive to conventional therapies.
Panelists discuss the current and future roles of advanced treatments, including biologics and Bruton tyrosine kinase (BTK) inhibitors, in the management of chronic spontaneous urticaria (CSU), highlighting their potential to improve patient outcomes and the evolving landscape of treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe what you see as the current and future role of advanced treatments such as biologics and BTK inhibitors in CSU management?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
2
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
3
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
4
CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D
5
























































